巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-08-17
2021-12-05
2022-02-08
2023-08-05
2023-03-10
2022-07-27
2021-11-02
2023-09-27
2021-09-23
2022-07-29
2021-09-22
2022-07-28